Pharmacotherapy in Down's syndrome: Which way forward?

Fabian Fernandez; Jamie O. Edgin

doi:10.1016/S1474-4422(16)30056-4

Pharmacotherapy in Down's syndrome: Which way forward?

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	776-777
Number of pages	2
Journal	The Lancet Neurology
Volume	15
Issue number	8
DOIs	https://doi.org/10.1016/S1474-4422(16)30056-4
State	Published - Jul 1 2016

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(16)30056-4

Cite this

@article{722eb75dd3c64af399c98f3d58c995b6,

title = "Pharmacotherapy in Down's syndrome: Which way forward?",

author = "Fabian Fernandez and Edgin, {Jamie O.}",

note = "Funding Information: JOE reports grants from the LuMind Research Down Syndrome Foundation, grants and personal fees from Hoffman La Roche Ltd, personal fees from Novartis, grants from the Lejeune Foundation, grants from the Bill & Melinda Gates Foundation, and grants from the National Institutes of Health, outside the submitted work; JOE has a patent (US patent 20 150 379 877), System and Methods for Neuropsychological Assessment pending to the University of Arizona. FF has a patent (US patent 8 729 067, 2014), Pharmacological Treatment of Cognitive Impairment, issued; this patent, of which he is an inventor, has been licensed by Stanford University to Balance Therapeutics and as part of the licensing agreement, Stanford University transferred a small share of Balance Therapeutics stock to him in 2010–11.",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/S1474-4422(16)30056-4",

language = "English (US)",

volume = "15",

pages = "776--777",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "8",

}

TY - JOUR

T1 - Pharmacotherapy in Down's syndrome

T2 - Which way forward?

AU - Fernandez, Fabian

AU - Edgin, Jamie O.

N1 - Funding Information: JOE reports grants from the LuMind Research Down Syndrome Foundation, grants and personal fees from Hoffman La Roche Ltd, personal fees from Novartis, grants from the Lejeune Foundation, grants from the Bill & Melinda Gates Foundation, and grants from the National Institutes of Health, outside the submitted work; JOE has a patent (US patent 20 150 379 877), System and Methods for Neuropsychological Assessment pending to the University of Arizona. FF has a patent (US patent 8 729 067, 2014), Pharmacological Treatment of Cognitive Impairment, issued; this patent, of which he is an inventor, has been licensed by Stanford University to Balance Therapeutics and as part of the licensing agreement, Stanford University transferred a small share of Balance Therapeutics stock to him in 2010–11.

PY - 2016/7/1

Y1 - 2016/7/1

UR - http://www.scopus.com/inward/record.url?scp=84973299598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973299598&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(16)30056-4

DO - 10.1016/S1474-4422(16)30056-4

M3 - Comment/debate

C2 - 27302343

AN - SCOPUS:84973299598

SN - 1474-4422

VL - 15

SP - 776

EP - 777

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 8

ER -

Pharmacotherapy in Down's syndrome: Which way forward?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this